Do Weon Lee1, Han-Soo Kim1,2, Ilkyu Han3,4. 1. Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, South Korea. 2. Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul, South Korea. 3. Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, South Korea. hik19@snu.ac.kr. 4. Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul, South Korea. hik19@snu.ac.kr.
Abstract
BACKGROUND: Actuarial survival based on the Kaplan-Meier method can overestimate actual long-term survival, especially among those with factors of poor prognosis. Patients with American Joint Committee on Cancer stage III soft tissue sarcoma (STS) represent a subset with a high risk of STS-specific mortality. Therefore, we aimed to characterize the clinicopathological characteristics associated with actual long-term survival in patients with stage III STS. METHODS: We retrospectively reviewed 116 patients who underwent surgical resection for stage III STS with curative intent between March 2000 and December 2013. Long-term survivors (n = 61), defined as those who survived beyond 5 years, were compared with short-term survivors (n = 36), who died of STS within 5 years. RESULTS: Multivariate logistic regression analyses showed that a tumor size < 10 cm [odds ratio (OR) 3.95, p = 0.047], histological grade of 2 (OR 8.12, p = 0.004), and American Society of Anesthesiologists (ASA) score of 1 (OR 11.25, p = 0.001) were independently associated with actual 5-year survival. However, 66% of the long-term survivors exhibited factors of poor prognosis: 36% had a tumor size > 10 cm and 48% had a histological grade of 3. Leiomyosarcoma (3 of 10) was negatively associated with actual long-term survival. CONCLUSIONS: Actual 5-year survival after resection of stage III STS was associated with tumor size, histological grade, and ASA score. However, majority of the actual 5-year survivors exhibit factors of poor prognosis, suggesting that aggressive treatment should be offered for a chance of long-term survival in these patients.
BACKGROUND: Actuarial survival based on the Kaplan-Meier method can overestimate actual long-term survival, especially among those with factors of poor prognosis. Patients with American Joint Committee on Cancer stage III soft tissue sarcoma (STS) represent a subset with a high risk of STS-specific mortality. Therefore, we aimed to characterize the clinicopathological characteristics associated with actual long-term survival in patients with stage III STS. METHODS: We retrospectively reviewed 116 patients who underwent surgical resection for stage III STS with curative intent between March 2000 and December 2013. Long-term survivors (n = 61), defined as those who survived beyond 5 years, were compared with short-term survivors (n = 36), who died of STS within 5 years. RESULTS: Multivariate logistic regression analyses showed that a tumor size < 10 cm [odds ratio (OR) 3.95, p = 0.047], histological grade of 2 (OR 8.12, p = 0.004), and American Society of Anesthesiologists (ASA) score of 1 (OR 11.25, p = 0.001) were independently associated with actual 5-year survival. However, 66% of the long-term survivors exhibited factors of poor prognosis: 36% had a tumor size > 10 cm and 48% had a histological grade of 3. Leiomyosarcoma (3 of 10) was negatively associated with actual long-term survival. CONCLUSIONS: Actual 5-year survival after resection of stage III STS was associated with tumor size, histological grade, and ASA score. However, majority of the actual 5-year survivors exhibit factors of poor prognosis, suggesting that aggressive treatment should be offered for a chance of long-term survival in these patients.
Authors: Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides Journal: J Surg Oncol Date: 2016-09-16 Impact factor: 3.454
Authors: Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo Journal: Ann Surg Oncol Date: 2016-12-05 Impact factor: 5.344
Authors: Jorge R Toro; Lois B Travis; Hongyu Julian Wu; Kangmin Zhu; Christopher D M Fletcher; Susan S Devesa Journal: Int J Cancer Date: 2006-12-15 Impact factor: 7.396
Authors: Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Peter W M Chung; Benjamin M Deheshi; Peter C Ferguson; Jay S Wunder; Anthony M Griffin; Charles N Catton; Robert S Bell; Lawrence M White; Rita A Kandel; Brian O'Sullivan Journal: Cancer Date: 2009-07-15 Impact factor: 6.860
Authors: Attila Kollár; Christian Rothermundt; Frank Klenke; Beata Bode; Daniel Baumhoer; Volker Arndt; Anita Feller Journal: Cancer Epidemiol Date: 2019-09-11 Impact factor: 2.984
Authors: Linus Hyunsuk Lee; Sarah Tepper; Grant Owen; Dian Wang; Nicolas Lopez-Hisijos; Matthew W Colman; Steven Gitelis; Alan T Blank Journal: Radiat Oncol J Date: 2022-09-06